Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Karn

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Human Pathology|January 24, 2006
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neuRaihanatou Diallo, Achim Rody, Christian Jackisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1Achim Rody, Uwe Holtrich, Regine Gaetje, et al.
Plos One|January 6, 2012
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signaturesThomas Karn, Lajos Pusztai, Uwe Holtrich, et al.
Molecular and Clinical Oncology|November 29, 2017
Claudin-1 expression in cervical cancerFriederike Hoellen, Annika Waldmann, Constanze Banz-Jansen, et al.
Cancers|August 25, 2019
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto TrialMalgorzata Banys-Paluchowski, Sibylle Loibl, Isabell Witzel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentationThomas Karn, Lajos Pusztai, Eugen Ruckhäberle, et al.
British Journal of Cancer|November 16, 2019
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trialIsabell Witzel, Sibylle Loibl, Ralph Wirtz, et al.
BMC Medicine|October 11, 2018
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trialInes Stevic, Volkmar Müller, Karsten Weber, et al.
Cancer Cell International|March 17, 2023
The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patientsFrancesca Reimer, Sarah Bryan, Karen Legler, et al.
Cancer Research|September 13, 2015
CD73 is associated with poor prognosis in high-grade serous ovarian cancerMartin Turcotte, Kathleen Spring, Sandra Pommey, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Human Pathology|January 24, 2006
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neuRaihanatou Diallo, Achim Rody, Christian Jackisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1Achim Rody, Uwe Holtrich, Regine Gaetje, et al.
Plos One|January 6, 2012
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signaturesThomas Karn, Lajos Pusztai, Uwe Holtrich, et al.
Molecular and Clinical Oncology|November 29, 2017
Claudin-1 expression in cervical cancerFriederike Hoellen, Annika Waldmann, Constanze Banz-Jansen, et al.
Cancers|August 25, 2019
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto TrialMalgorzata Banys-Paluchowski, Sibylle Loibl, Isabell Witzel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentationThomas Karn, Lajos Pusztai, Eugen Ruckhäberle, et al.
British Journal of Cancer|November 16, 2019
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trialIsabell Witzel, Sibylle Loibl, Ralph Wirtz, et al.
BMC Medicine|October 11, 2018
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trialInes Stevic, Volkmar Müller, Karsten Weber, et al.
Cancer Cell International|March 17, 2023
The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patientsFrancesca Reimer, Sarah Bryan, Karen Legler, et al.
Cancer Research|September 13, 2015
CD73 is associated with poor prognosis in high-grade serous ovarian cancerMartin Turcotte, Kathleen Spring, Sandra Pommey, et al.
Pageof 11